Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model.
Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, Howell A, Ingle J; Breast Cancer Prevention Collaborative Group.
Santen RJ, et al.
Endocr Relat Cancer. 2007 Jun;14(2):169-87. doi: 10.1677/ERC-06-0045.
Endocr Relat Cancer. 2007.
PMID: 17639036
Review.
The majority of candidates for breast cancer prevention have not accepted tamoxifen because of the perception of an unfavorable risk/benefit ratio and the acceptance of raloxifene remains to be determined. One means of improving this ratio is to identify women at very high …
The majority of candidates for breast cancer prevention have not accepted tamoxifen because of the perception of an unfavorable risk/ …